Transthyretin Amyloidosis (ATTR)

Heart Failure Association (HFA) 2025

Congress Details

calander17-20 May 2025 | Serbia

locationBelgrade, Serbia

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Oral

Congress Materials

Cardiomyopathy-Analysis
icon Presentation Type
Presentation
location icon Location
Belgrade, Serbia
icon Title
Vutrisiran reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with transthyretin amyloid cardiomyopathy: Analysis from the HELIOS-B trial
Cardiomyopathy-AReal
icon Presentation Type
Poster
location icon Location
Belgrade, Serbia
icon Title
Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan
hATTR-Patients
icon Presentation Type
Poster
location icon Location
Belgrade, Serbia
icon Title
Utility of Genetic Testing For Diagnosing hATTR Patients: Results from a European and Middle East Genetic Testing Program
Vutrisiran-in-Patients
icon Presentation Type
Presentation
location icon Location
Belgrade, Serbia
icon Title
Vutrisiran In Patients With Transthyretin Amyloidosis with Cardiomyopathy In HELIOS-B Who Had Progressed On Tafamidis

Associated Materials

ISPOR-Glasgow-UK-Mobile

Transthyretin Amyloidosis (ATTR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025

9-12 November, 2025 UK

View Details
Preparation Date
March 2026
Job Code
MB-UK-00098

Transthyretin Amyloidosis (ATTR)

Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis

Journal of Clinical Medicine

Author(s)

Akash Singh, John Wyatt, Marie Théaudin, et al

September 2025

Preparation Date
March 2026
Job Code
MB-UK-00162

Transthyretin Amyloidosis (ATTR)

Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicentre Study

Annals of Medicine

Author(s)

Yessar Hussain, Saurabh Malhotra, Brett W. Sperry, et al

September 2025

Preparation Date
March 2026
Job Code
MB-UK-00163

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B

Journal of the American College of Cardiology

Author(s)

Mathew S. Maurer, John L. Berk, Thibaud Damy, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00164

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Karola S. Jering, Marianna Fontana, Hicham Skali, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00165

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial

Nature Medicine

Author(s)

Karola S. Jering, Marianna Fontana, Olivier Lairez, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00166
Preparation Date
March 2026
Job Code
MB-UK-00127